Edwards Lifesciences (EW) closed at $107.15 on November 13, 2026, up 1.3% from the previous close, on volume of 3,549,640 shares (30-day average 4,394,312).
Data as of November 13, 2026.
13-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 30, 2026 | Condor Ratio With Calls (Skip Strike) | 20-Nov-2690[3x] : 97.5[3x] : 100 : 110[2x] C | 9,000 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 13, 2026. See the 10 largest for 30, 60 and 90 days
Edwards Updates ECLIPTIS Heart Device Study: What EW Investors Should Know
TipRanks (Fri, 13-Nov 11:31 AM ET)
Edwards Lifesciences Reports Third Quarter Results
Business Wire (Wed, 4-Nov 4:15 PM ET)
Business Wire (Mon, 2-Nov 1:25 PM ET)
Business Wire (Mon, 2-Nov 12:40 PM ET)
Business Wire (Wed, 21-Oct 9:00 AM ET)
Edwards Lifesciences to Host Earnings Conference Call on November 4, 2026
Business Wire (Wed, 7-Oct 6:00 AM ET)
Edwards Lifesciences to Host Investor Event in Conjunction With TCT
Business Wire (Mon, 5-Oct 6:00 AM ET)
Business Wire (Thu, 1-Oct 4:26 PM ET)
Edwards Lifesciences Comments on TAVR National Coverage Decision
Business Wire (Thu, 10-Sep 5:49 PM ET)
Did Edwards Lifesciences Corporation Insiders Breach their Fiduciary Duties to Shareholders?
PRNewswire (Mon, 7-Sep 3:32 PM ET)
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
Edwards Lifesciences trades on the NYSE stock market under the symbol EW.
As of November 13, 2026, EW stock price climbed to $107.15 with 3,549,640 million shares trading.
EW has a beta of 0.32, meaning it tends to be less sensitive to market movements. EW has a correlation of 0.02 to the broad based SPY ETF.
EW has a market cap of $61.61 billion. This is considered a Large Cap stock.
Last quarter Edwards Lifesciences reported $2 billion in Revenue and $.80 earnings per share. This beat revenue expectation by $39 million and exceeded earnings estimates by $.06.
In the last 3 years, EW traded as high as $107.69 and as low as $58.93.
The top ETF exchange traded funds that EW belongs to (by Net Assets): VTI, VOO, VO, IVV, SPY.
EW has outperformed the market in the last year with a price return of +24.4% while the SPY ETF gained +13.4%. EW has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +15.8% and +16.5%, respectively, while the SPY returned -2.8% and -0.2%, respectively.
EW support price is $103.52 and resistance is $108.08 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that EW shares will trade within this expected range on the day.